{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:21:27Z","timestamp":1788510087546,"version":"build-2803163510"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Cancer Center Climbing Foundation","award":["NCC201908A02"],"award-info":[{"award-number":["NCC201908A02"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"abstract":"<jats:p>Gastric cancer (GC) exhibits marked heterogeneity, patients with identical stage receive divergent outcomes. Metabolic reprogramming and aging are pivotal in reshaping the tumor microenvironment. However, their interplay in GC prognosis remains unexplored. We analyzed RNA-seq and clinical data from The Cancer Genome Atlas Program and Gene Expression Omnibus databases. Using univariate Cox, LASSO, and multivariate Cox regression, we identified candidate genes and constructed a prognostic signature. Immune contexture, genomic alterations and drug sensitivity were compared between high- and low-risk group. The metabolic and aging related risk score, comprising 4 genes (GNAI1, GSTA1, APOC3, and LOX), was developed. Validation across multiple cohorts confirmed its robust prognostic performance. The model also effectively stratified patients into distinct risk subgroups with differential immune profiles and responses to immunotherapy. Notably, high-risk patients showed reduced sensitivity to common chemotherapeutic agents but may benefit from targeting the PI3K\/mTOR pathway. Metabolic and aging related risk score serves as a promising tool for individualized risk assessment and therapeutic guidance in GC, warranting further clinical validation.<\/jats:p>","DOI":"10.1097\/md.0000000000046616","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T04:00:35Z","timestamp":1766203235000},"page":"e46616","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic and aging related gene risk score for therapeutic stratification and precision oncology in gastric cancer"],"prefix":"10.1097","volume":"104","author":[{"given":"Yue","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Endoscopy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Zheng","sequence":"additional","affiliation":[{"name":"College of Clinical Medicine, China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlai","family":"Liu","sequence":"additional","affiliation":[{"name":"Affiliated Cancer Hospital of Inner Mongolia Medical University, Inner Mongolia Autonomous Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4079-8945","authenticated-orcid":false,"given":"Shangwei","family":"Ning","sequence":"additional","affiliation":[{"name":"College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-586X","authenticated-orcid":false,"given":"Yu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260522","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260522","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer.","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"R3-20260522","doi-asserted-by":"crossref","first-page":"e171087","DOI":"10.1001\/jamasurg.2017.1087","article-title":"Association of adjuvant chemotherapy with survival in patients with stage II or III gastric cancer.","volume":"152","author":"Jiang","year":"2017","journal-title":"JAMA Surg"},{"key":"R4-20260522","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tem.2024.07.009","article-title":"Exploring the heterogeneous targets of metabolic aging at single-cell resolution.","volume":"36","author":"Sun","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"Suppl 1","key":"R5-20260522","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/geront\/gnz038","article-title":"Cancer risk among older adults: time for cancer prevention to go silver.","volume":"59","author":"White","year":"2019","journal-title":"Gerontologist"},{"key":"R6-20260522","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/cac2.12591","article-title":"Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment.","volume":"44","author":"Zhang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"R7-20260522","doi-asserted-by":"crossref","first-page":"1099624","DOI":"10.3389\/fonc.2023.1099624","article-title":"Gradual deterioration of fatty liver disease to liver cancer via inhibition of AMPK signaling pathways involved in energy-dependent disorders, cellular aging, and chronic inflammation.","volume":"13","author":"Meng","year":"2023","journal-title":"Front Oncol"},{"key":"R8-20260522","doi-asserted-by":"crossref","first-page":"eabq0615","DOI":"10.1126\/sciadv.abq0615","article-title":"Chronic exposure to carbon black ultrafine particles reprograms macrophage metabolism and accelerates lung cancer.","volume":"8","author":"Chang","year":"2022","journal-title":"Sci Adv"},{"key":"R9-20260522","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41590-018-0226-8","article-title":"Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages.","volume":"19","author":"Bohn","year":"2018","journal-title":"Nat Immunol"},{"key":"R10-20260522","doi-asserted-by":"crossref","first-page":"e004337","DOI":"10.1136\/jitc-2021-004337","article-title":"Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion.","volume":"10","author":"Song","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"R11-20260522","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1002\/1878-0261.13268","article-title":"Cellular senescence and the tumour microenvironment.","volume":"16","author":"Takasugi","year":"2022","journal-title":"Mol Oncol"},{"key":"R12-20260522","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.","volume":"15","author":"Tie","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R13-20260522","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.celrep.2019.08.068","article-title":"Restricting glycolysis preserves T Cell effector functions and augments checkpoint therapy.","volume":"29","author":"Renner","year":"2019","journal-title":"Cell Rep"},{"key":"R14-20260522","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial.","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"R15-20260522","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ijc.34296","article-title":"First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CHECKMATE 649 Chinese subgroup analysis.","volume":"152","author":"Liu","year":"2023","journal-title":"Int J Cancer"},{"key":"R16-20260522","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"R17-20260522","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"R18-20260522","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-10-2180","article-title":"Gene expression signature-based prognostic risk score in gastric cancer.","volume":"17","author":"Cho","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R19-20260522","doi-asserted-by":"crossref","first-page":"933798","DOI":"10.3389\/fgene.2022.933798","article-title":"A novel ten-gene prognostic signature for cervical cancer based on CD79B-related immunomodulators.","volume":"13","author":"Pu","year":"2022","journal-title":"Front Genet"},{"key":"R20-20260522","doi-asserted-by":"crossref","first-page":"584213","DOI":"10.3389\/fonc.2021.584213","article-title":"A four-gene-based risk score with high prognostic value in gastric cancer.","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"R21-20260522","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.7150\/jca.104389","article-title":"Cholesterol metabolism-related genes predict immune infiltration and prognosis in gastric cancer patients.","volume":"16","author":"Liu","year":"2025","journal-title":"J Cancer"},{"key":"R22-20260522","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann Oncol"},{"key":"R23-20260522","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection.","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"R24-20260522","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1038\/s41467-022-32552-1","article-title":"A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues.","volume":"13","author":"Saul","year":"2022","journal-title":"Nat Commun"},{"key":"R25-20260522","doi-asserted-by":"crossref","first-page":"D1083","DOI":"10.1093\/nar\/gkx1042","article-title":"Human ageing genomic resources: new and updated databases.","volume":"46","author":"Tacutu","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"R26-20260522","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"R27-20260522","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer.","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"R28-20260522","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13073-020-0721-z","article-title":"Large-scale public data reuse to model immunotherapy response and resistance.","volume":"12","author":"Fu","year":"2020","journal-title":"Genome Med"},{"key":"R29-20260522","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1002\/1878-0261.13261","article-title":"Metabolic reprogramming: a bridge between aging and tumorigenesis.","volume":"16","author":"Drapela","year":"2022","journal-title":"Mol Oncol"},{"key":"R30-20260522","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","article-title":"CD4(+) T cells in antitumor immunity.","volume":"10","author":"Montauti","year":"2024","journal-title":"Trends Cancer"},{"key":"R31-20260522","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.4049\/jimmunol.2100852","article-title":"Tissue-resident memory CD4(+) T Cells play a dominant role in the initiation of antitumor immunity.","volume":"208","author":"Zhang","year":"2022","journal-title":"J Immunol"},{"key":"R32-20260522","doi-asserted-by":"crossref","first-page":"eabe3348","DOI":"10.1126\/sciadv.abe3348","article-title":"Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.","volume":"7","author":"Cachot","year":"2021","journal-title":"Sci Adv"},{"key":"R33-20260522","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12967-020-02273-4","article-title":"Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.","volume":"18","author":"Toomey","year":"2020","journal-title":"J Transl Med"},{"key":"R34-20260522","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41556-019-0287-4","article-title":"NAD(+) metabolism governs the proinflammatory senescence-associated secretome.","volume":"21","author":"Nacarelli","year":"2019","journal-title":"Nat Cell Biol"},{"key":"R35-20260522","doi-asserted-by":"crossref","first-page":"e001536","DOI":"10.1136\/jitc-2020-001536","article-title":"Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.","volume":"9","author":"Gao","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R36-20260522","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"R37-20260522","first-page":"223","article-title":"YME1L overexpression exerts pro-tumorigenic activity in glioma by promoting G\u03b1i1 expression and Akt activation.","volume":"14","author":"Liu","year":"2023","journal-title":"Protein Cell"},{"key":"R38-20260522","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1038\/s41388-021-01812-7","article-title":"LncRNA PINK1-AS promotes G\u03b1i1-driven gastric cancer tumorigenesis by sponging microRNA-200a.","volume":"40","author":"Lv","year":"2021","journal-title":"Oncogene"},{"key":"R39-20260522","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/cells11203232","article-title":"Glutathione S-transferases S1, Z1 and A1 serve as prognostic factors in glioblastoma and promote drug resistance through antioxidant pathways.","volume":"11","author":"Cheng","year":"2022","journal-title":"Cells"},{"key":"R40-20260522","doi-asserted-by":"crossref","first-page":"107490","DOI":"10.1016\/j.phrs.2024.107490","article-title":"GSTA1\/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma.","volume":"210","author":"Ma","year":"2024","journal-title":"Pharmacol Res"},{"key":"R41-20260522","doi-asserted-by":"crossref","first-page":"12777","DOI":"10.3390\/ijms232112777","article-title":"ENO1 Binds to ApoC3 and impairs the proliferation of T Cells via IL-8\/STAT3 Pathway in OSCC.","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R42-20260522","doi-asserted-by":"crossref","first-page":"12270","DOI":"10.3390\/ijms232012270","article-title":"Lysyl oxidase family proteins: prospective therapeutic targets in cancer.","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R43-20260522","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3748\/wjg.v25.i15.1828","article-title":"Lysyl oxidase and hypoxia-inducible factor 1\u03b1: biomarkers of gastric cancer.","volume":"25","author":"Han","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R44-20260522","doi-asserted-by":"crossref","first-page":"111462","DOI":"10.1016\/j.cellsig.2024.111462","article-title":"CAF-secreted LOX promotes PD-L1 expression via histone lactylation and regulates tumor EMT through TGF\u03b2\/IGF1 signaling in gastric Cancer.","volume":"124","author":"Li","year":"2024","journal-title":"Cell Signal"},{"key":"R45-20260522","doi-asserted-by":"crossref","first-page":"760470","DOI":"10.3389\/fcell.2021.760470","article-title":"lncRNA\/miR-29c-mediated high expression of LOX can influence the immune status and chemosensitivity and can forecast the poor prognosis of gastric cancer.","volume":"9","author":"Nai","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R46-20260522","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth.","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"R47-20260522","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/cancers14010218","article-title":"Microsatellite instability, Epstein-Barr virus, and programmed cell death ligand 1 as predictive markers for immunotherapy in gastric cancer.","volume":"14","author":"Yu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R48-20260522","doi-asserted-by":"crossref","first-page":"e2100712","DOI":"10.1002\/advs.202100712","article-title":"Multifunctional nanodrug mediates synergistic photodynamic therapy and MDSCs-targeting immunotherapy of colon cancer.","volume":"8","author":"Ding","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"R49-20260522","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00262-024-03779-2","article-title":"Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature.","volume":"73","author":"Xu","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"R50-20260522","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejca.2021.08.029","article-title":"PI3K\u03b3\u03b4 inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.","volume":"157","author":"Han","year":"2021","journal-title":"Eur J Cancer"},{"key":"R51-20260522","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells.","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:02:13Z","timestamp":1779433333000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":51,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046616","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"2025-07-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}